01833 PA GOODDOCTOR
- 11.860
- +0.160+1.37%
PA GOODDOCTOR News
Ping An Family Doctor has upgraded strongly, and Ping An Health (01833) has surged by more than 3%.
According to Zhongtong Finance APP, on June 19, the stock price of Ping An Healthcare (01833), a Hong Kong Internet medical enterprise, rose by more than 3%. Recently, Ping An Health announced the comprehensive upgrade of its family doctor service brand "Ping An Family Doctor" and launched the 11312 one-stop proactive health management service system. This marks the formal formation of the dual-core hubs of management-style medical care for "family doctors" and "retirement butlers", and the synergy of medical care, retirement and insurance business will be further accelerated. It is understood that the market positioning of Ping An Family Doctor is very clear, mainly to provide services to Ping An Group's F-end and B-end customers. Its F2C and B2C models.
Hong Kong Shares Rebound 2.9% Amid Positive Sentiment
Hong Kong's Hang Seng Index extended early gains to close 2.9% higher at 18430.39. There could be some optimism among investors that more may be done by the Chinese authorities in 2H, IG market strate
Ping An Healthcare and Technology (HKG:1833) Adds HK$582m to Market Cap in the Past 7 Days, Though Investors From Three Years Ago Are Still Down 86%
As every investor would know, not every swing hits the sweet spot. But you want to avoid the really big losses like the plague. So take a moment to sympathize with the long term shareholders of Ping
Hang Seng Index Likely to Consolidate Between 18500-20000 Near Term
0642 GMT - Hong Kong's Hang Seng Index is likely to consolidate between 18500 and 20000 in the near term, according to CCB International analysts Cliff Zhao and Wilson Zou in a research note. They say
Despite slow growth, Ali Health is gradually becoming “healthy”
Jinwu Financial News | On May 27, Alibaba Health (00241.HK) announced its annual results for the 2024 fiscal year ending March 31, 2024. During the reporting period, it achieved revenue of 27.027 billion yuan, a slight increase of 1.0% year on year, and realized net profit of 883 million yuan, an increase of 64.6% year on year, with a significant increase in profit against the backdrop of flat revenue growth. The number of members of over 77 million and a MAU of up to 300 million have made Ali Health's current earnings report very popular. Driven by the results, Alibaba Health Hong Kong stock surged 10% on the 28th.
Trending Industry Today: ALI HEALTH Leads Gains In Digital Health Stocks
May 28th - The industry of $Digital Health(LIST1251.HK)$ is trending higher today with 4 constituents up and ALI HEALTH leading Gains.$ALI HEALTH(00241.HK)$ rises 11.72% to HK$3.43 with a turnover of
Ping An Healthcare and Technology Company Limited (HKG:1833) Is Expected To Breakeven In The Near Future
Ping An Healthcare and Technology Company Limited (HKG:1833) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Ping An Healthcare and T
Ping An Health (01833) was selected as “2024 Forbes China Brand Value Series Selection”
Recently, Forbes China released the results of the “2024 Forbes China Brand Value Series Selection”, and Ping An Health (01833) was selected as the “2024 Forbes China Brand Value Series Selection” — the “Top 50 Best Brands of the Year”.
Changes in Hong Kong stocks | Ping An Health (01833) rose more than 5% in the intraday period to launch Guangzhou Medical Insurance Online Payment and Drug Purchase Service
The Zhitong Finance App learned that Ping An Health (01833) rose more than 5% in the intraday period. As of press release, it had risen 4.09% to HK$10.18, with a turnover of HK$307.35,800. According to the news, Ping An Health announced that after announcing the launch of the online medical insurance drug purchase service in Dongguan at the end of March, online medical insurance payments have now also been implemented in Guangzhou. This time, Guangzhou Medical Insurance also supports co-ordinated accounts and personal accounts to provide users with new payment options, further enhance the convenience of online drug purchases, and reduce the financial burden on citizens. The person in charge of Ping An Health said that in the future, Ping An Health will continue in other cities across the country
Ping An Healthcare and Technology Company Limited's (HKG:1833) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
The Ping An Healthcare and Technology Company Limited (HKG:1833) share price has fared very poorly over the last month, falling by a substantial 26%. Instead of being rewarded, shareholders who hav
Public Companies Among Ping An Healthcare and Technology Company Limited's (HKG:1833) Largest Stockholders and Were Hit After Last Week's 15% Price Drop
Key Insights Significant control over Ping An Healthcare and Technology by public companies implies that the general public has more power to influence management and governance-related decisions A
Online medical insurance payments connect the cities of Dongguan and Guangzhou! Ping An Health (01833) Advances Multiple Ways to Innovate Internet Healthcare
Ping An of China (02318)'s high-speed railway connecting healthcare services to the main financial industry is being consolidated at an accelerated pace.
PA GOODDOCTOR: Annual Report 2023
The value of Ping An of China's (02318) 2023 earnings report has been underestimated by the market
Entering a new growth trajectory
Changes in Hong Kong stocks | Dr. Ping An (01833) bucked the market and turned upward, and the front-end back-end strategy progressed smoothly and was well received by many major international companies after the company's performance
The Hang Seng Index plummeted by more than 2% in the intraday period, and Ping An Good Doctor (01833) rebounded and increased by more than 8% after the results. As of press release, it rose 1.22% to HK$13.3, with a turnover of HK$34.831 million.
Analysts Have Been Trimming Their Ping An Healthcare and Technology Company Limited (HKG:1833) Price Target After Its Latest Report
Shareholders of Ping An Healthcare and Technology Company Limited (HKG:1833) will be pleased this week, given that the stock price is up 13% to HK$13.14 following its latest full-year results. I
Ping An Good Doctor's front-end and back-end strategy progressed smoothly, and Daimo raised the target price to HK$21
Morgan Stanley published a research report on Safe Doctor (01833) on March 20, 2024. The bank's analysts said that considering the company's adjusted net loss was further reduced, and the front-end+back-end 'expansion progressed smoothly,” the target price set for Ping An Good Doctor was HK$21, which meant that the stock had room to rise by 71%. The report shows that in the second half of 2023, Ping An Good Doctor's revenue increased 10.3% year-on-year. By business segment, the medical service business grew 0.8% year on year in the second half of 2023, and the health service business grew 18 year on year.
Dahua Jixian: Strategic business is expected to achieve double-digit growth and maintain Ping An Good Doctor (01833) “buy” rating
Dahua Jixian released a research report, maintaining the “Buy” rating of Ping An Good Doctor (01833) and assigning a target price of HK$15.
Ping An Good Doctor (01833)'s front-end and back-end strategy progressed smoothly, and Daimo raised the target price to HK$21
Morgan Stanley set a target price of HK$21 for Ping An Good Doctor, which means that the stock has room to rise 71%.
UBS: Strategy 2.0 has achieved results and a target price of HK$20 for Safe Doctor (01833)
The Zhitong Finance App learned that UBS (UBS), a major international bank, recently released a research report setting a target price of HK$20 for Ping An Good Doctor (01833), stressing that the company's 2023 performance was in line with expectations, that the steady progress of Strategy 2.0 reduced losses rapidly, and that steady growth in the F-side business was compounded by rapid B-side business growth. UBS commented in the research report that in 2023, the company achieved revenue of 4.7 billion yuan, in line with market expectations; net loss in 2023 and net loss adjusted under non-IFRS standards were 335 million yuan and 315 million yuan respectively, compared to the same period last year
Analysis
Price Target
No Data
